- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01904396
Identification of Carnitine-Responsive Cardiomyopathy (C001)
Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.
Study Overview
Detailed Description
The primary objective of this research is to determine the prevalence of primary and secondary (genetic and acquired) carnitine deficiency in patients with limb girdle weakness and hypertrophic or idiopathic dilated cardiomyopathy where an underlying cause is unknown. Identification and treatment with carnitine may potentially reverse or halt heart failure and skeletal muscle weakness in these patients.
Specific aims:
- To ascertain the prevalence of primary and secondary carnitine deficiency in a population of adults with myopathy and hypertrophic and dilated cardiomyopathy of unknown etiology
- To describe the demographic and phenotypic characteristics of patients with myopathy and dilated or hypertrophic cardiomyopathy who have primary and secondary carnitine deficiency
- To measure the motor and cardiovascular response to carnitine supplementation in patients with myopathy, cardiomyopathy and carnitine deficiency
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Hanna Faghfoury
- Email: hanna.faghfoury@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- University Health Network
-
Principal Investigator:
- Hanna Faghfoury, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- An adult patient (>18 years) with a diagnosis of either hypertrophic or dilated cardiomyopathy, for which the underlying etiology of the cardiomyopathy is unknown.
Exclusion Criteria:
- A history of ischemia
- A documented or suspected infection including HIV
- A history of severe longstanding hypertension
- A history of valvular heart disease
- A history of chemotherapy exposure
- A history of alcohol abuse
- Carnitine supplementation at the time of recruitment
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CarnitineDeficient
Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
|
Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Carnitine Concentration
Time Frame: Baseline
|
Measurement of free and total serum carnitine concentrations will be performed using isotope-dilution mass spectrometry.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Echocardiographic Measures
Time Frame: Baseline, every 6m for up to 2 years
|
Measurements include: Septal diameter Left Ventricular (LV) mass LV ejection fraction LV end-systolic volume LV end-diastolic measure |
Baseline, every 6m for up to 2 years
|
B-Natriuretic Peptide (BNP)
Time Frame: Baseline, every 6m for up to 2 years
|
An elevated BNP level is a marker of increased LV filling pressures and LV dysfunction and is highly correlated with severity of, and prognosis in, heart failure.
BNP testing is routinely performed at the cardiac clinic at University Health Network to determine treatment response and to assist with risk stratification prognostication in patients with heart failure.
|
Baseline, every 6m for up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Faghfoury Hannaneh, MD, University Health Network, Toronto, Ontario
- Principal Investigator: Ingrid Tein, MD, The Hospital for Sick Children, Toronto, Ontario
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Carnitine001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carnitine Deficiency
-
Ain Shams UniversityRecruitingCarnitine Deficiency Due to HemodialysisEgypt
-
Karen Lindhardt MadsenRigshospitalet, DenmarkCompletedCarnitine Transporter, Plasma-membrane, Deficiency of
-
Ultragenyx Pharmaceutical IncCompletedCarnitine Palmitoyltransferase (CPT I or CPT II) Deficiency | Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency | Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency | Trifunctional Protein (TFP) Deficiency | Carnitine-acylcarnitine Translocase (CACT) DeficiencyUnited States, United Kingdom
-
University of California, San FranciscoCompletedCarnitine Transporter DeficiencyUnited States
-
Rigshospitalet, DenmarkGroupe Hospitalier Pitie-SalpetriereCompletedCarnitine Palmitoyltransferase II Deficiency | Very Long Chain Acyl Coa Dehydrogenase DeficiencyDenmark
-
Oregon Health and Science UniversityUniversity of PittsburghCompletedVery Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency | Carnitine Palmitoyltransferase 2 (CPT2) Deficiency | Mitochondrial Trifunctional Protein (TFP) Deficiency | Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) DeficiencyUnited States
-
Oregon Health and Science UniversityAlaska Department of Health and Social ServicesCompletedCarnitine Palmitoyl Transferase Type 1A (CPT1A) DeficiencyUnited States
-
Oregon Health and Science UniversityCompletedNormal Volunteers | Trifunctional Protein Deficiency | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency | Medium-chain Acyl-CoA Dehydrogenase Deficiency | Carnitine Palmitoyltransferase II Deficiency, MyopathicUnited States
-
West Kazakhstan Medical UniversityRecruitingOrnithine Transcarbamylase Deficiency | Biotinidase Deficiency | Citrullinemia | Glutaric Acidemia Type II | Argininosuccinic Aciduria | Maple Syrup Urine Disease | Primary Carnitine Deficiency | Homocystinuria | Carnitine Palmitoyltransferase II Deficiency | Arginase Deficiency | Very Long-chain Acyl-CoA... and other conditionsKazakhstan
-
Montefiore Medical CenterWithdrawnCarnitine IngestionUnited States
Clinical Trials on Carnitine
-
Vanderbilt University Medical CenterCompletedLung Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Carnitine Nutritional DeficiencyUnited States
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Ain Shams UniversityCompleted
-
Kochi UniversityUnknown
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Toujinkai HospitalCompletedDisorder of Fatty Acid Metabolism
-
Bahria UniversityUniversity of Karachi; Jinnah Postgraduate Medical Centre; Pakistan Navy Station...RecruitingHemodialysis ComplicationPakistan
-
National Taiwan University HospitalRecruitingGut Dysbiosis for TMAO Production From L-carnitine ConsumptionTaiwan
-
Ain Shams UniversityActive, not recruitingl Carnitine With Ketogenic DietEgypt
-
Heba Allah Ali Abd El-Halim MabroukTanta UniversityCompleted